What are the indications, efficacy, dosing, side effects, and drug interactions of Minipress (prazosin)?

Minipress (Prazosin): Clinical Overview

Minipress (prazosin) is an alpha-1 adrenergic receptor blocker FDA-approved for treating hypertension, with additional off-label uses for PTSD-related nightmares and benign prostatic hyperplasia (BPH).

FDA-Approved Indication

Hypertension Management

Prazosin lowers blood pressure by selectively blocking alpha-1 adrenergic receptors, causing vasodilation through relaxation of arteriolar smooth muscle 1. It reduces cardiovascular morbidity and mortality primarily through stroke prevention, though benefits extend to myocardial infarction risk reduction 1. The drug can be used as monotherapy or combined with diuretics or beta-blockers 1.

Dosing

Standard Hypertension Dosing:

• Initial dose: 1 mg at bedtime (to minimize first-dose hypotension) 2, 3, 4
• Maintenance dose: 2-20 mg daily, divided 2-3 times daily 2, 3, 4
• Typical effective range: 6-15 mg/day in divided doses

Extended-release formulation (Minipress XL): 10-20 mg once daily has demonstrated efficacy in mild-to-moderate hypertension 5.

PTSD-related nightmares (off-label):

• Start at 1 mg at bedtime with blood pressure monitoring
• Titrate gradually to 2-6 mg nightly for civilians 6
• Military populations may require 10-16 mg nightly 6
• Response typically occurs within weeks 6

Efficacy

For Hypertension: The JNC 7 guidelines classify prazosin as an alpha-1 blocker with documented blood pressure-lowering efficacy, though it is positioned as a secondary agent rather than first-line therapy 2. The 2017 ACC/AHA guidelines similarly list prazosin as a second-line option, noting it may be considered for patients with concomitant BPH 3, 4.

Prazosin causes less reflex tachycardia than non-selective alpha blockers or direct vasodilators while maintaining comparable efficacy to conventional agents like methyldopa and hydralazine 7. When combined with diuretics, it effectively controls moderate-to-severe hypertension 2.

For PTSD (off-label): A systematic review and meta-analysis found prazosin significantly more efficacious than placebo in reducing distressing dreams in PTSD patients 8. Multiple clinical trials support its efficacy for nightmares and sleep improvement, though evidence quality varies 9, 6.

Side Effects and Safety Concerns

Common adverse effects:

• Dizziness and drowsiness (especially after first dose) 1
• Headache and fatigue 5
• Orthostatic hypotension 3, 4

Serious concerns:

• First-dose hypotension/syncope: Monitor blood pressure after initial dose 1, 6
• Intraoperative Floppy Iris Syndrome (IFIS): Inform ophthalmologists before cataract surgery; do not discontinue prazosin pre-operatively 1
• Orthostatic hypotension: Particularly problematic in elderly patients 3, 4

Monitoring requirements:

• Blood pressure (especially after first dose and dose increases)
• Assess for dizziness, lightheadedness when standing
• Advise patients to rise slowly from lying/sitting positions 1

Drug Interactions

Additive hypotensive effects with:

• Other antihypertensives (diuretics, beta-blockers) - reduce prazosin to 1-2 mg three times daily when adding agents 1
• PDE-5 inhibitors (sildenafil, tadalafil) - can cause symptomatic hypotension 1

Minimal interactions reported with:

• Cardiac glycosides (digoxin)
• Hypoglycemics (insulin, oral agents)
• Antiarrhythmics (procainamide, quinidine)
• NSAIDs and analgesics 1

Laboratory interference:

• May cause false-positive pheochromocytoma screening (elevated VMA and norepinephrine metabolites) - discontinue prazosin and retest after one month if elevated 1

Contraindications and Precautions

Pregnancy: Category C - testicular changes observed in animal studies at high doses; limited human data (44 pregnant women) showed no fetal abnormalities 1

Renal/hepatic impairment: Use with caution; dose adjustment may be necessary 1

Avoid abrupt discontinuation: Taper when stopping, particularly when used with clonidine to prevent rebound hypertension 3, 4

Clinical Positioning

Current guideline recommendations position prazosin as:

• A second-line antihypertensive agent 2, 3, 4
• Not recommended as first-line unless patient has concomitant BPH 3, 4
• Thiazide diuretics, ACE inhibitors, ARBs, and calcium channel blockers remain preferred initial agents for hypertension 2

For PTSD nightmares: Consider prazosin for time-limited trials in patients with nightmare-dominant PTSD unresponsive to first-line trauma-focused psychotherapy and antidepressants, after excluding obstructive sleep apnea 9.